{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:25:28Z","timestamp":1792297528947,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.neurol.2024.09.008","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:54:45Z","timestamp":1729014885000},"page":"1087-1099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Migraine treatment: Position paper of the French Headache Society"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-0750","authenticated-orcid":false,"given":"X.","family":"Moisset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Demarquay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-9589","authenticated-orcid":false,"given":"S.","family":"de Gaalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Donnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gu\u00e9gan-Massardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7541-6916","authenticated-orcid":false,"given":"C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Valade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Corand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-2569","authenticated-orcid":false,"given":"C.","family":"Gollion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-5292","authenticated-orcid":false,"given":"N.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Grangeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lant\u00e9ri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-5013","authenticated-orcid":false,"given":"A.","family":"Ducros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.09.008_bib0340","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neurol.2021.07.001","article-title":"Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: diagnosis and assessment","volume":"177","author":"Demarquay","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0345","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neurol.2021.07.006","article-title":"Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment","volume":"177","author":"Ducros","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0350","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neurol.2021.07.009","article-title":"Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 3: non-pharmacological treatment","volume":"177","author":"Demarquay","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0355","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","article-title":"CGRP and migraine: from bench to bedside","volume":"177","author":"Edvinsson","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0360","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u00a0\u2013\u00a0successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0365","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u00a0\u2013\u00a02022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache J Head Face Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0375","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10194-024-01749-8","article-title":"An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity","volume":"25","author":"Griffin","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0380","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-024-01747-w","article-title":"Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis","volume":"25","author":"Pozo-Rosich","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0385","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine","volume":"23","author":"Khanal","year":"2022","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0390","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.neurol.2020.11.012","article-title":"Severe migraine and its control: a proposal for definitions and consequences for care","volume":"177","author":"Donnet","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0395","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.neurol.2023.01.730","article-title":"Study of severe migraine in general medicine","volume":"179","author":"Henri","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.09.008_bib0400","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0405","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10194-023-01593-2","article-title":"Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study","volume":"24","author":"Straube","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0410","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2024.09.008_bib0415","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.008_bib0420","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study","volume":"42","author":"Raffaelli","year":"2022","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0425","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine\u00a0\u2013\u00a0a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0430","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/03331024211018137","article-title":"CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis","volume":"41","author":"Frank","year":"2021","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0435","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2024.0368","article-title":"Early use of erenumab vs. nonspecific oral migraine preventives: the APPRAISE Randomized Clinical Trial","volume":"81","author":"Pozo-Rosich","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0440","first-page":"934","article-title":"A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response","volume":"16","author":"Hong","year":"2023","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.neurol.2024.09.008_bib0445","first-page":"461","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"81","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.09.008_bib0450","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s10194-023-01680-4","article-title":"One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study","volume":"24","author":"Lanteri-Minet","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0455","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221146315","article-title":"New migraine prophylactic drugs: current evidence and practical suggestions for non-responders to prior therapy","volume":"43","author":"Lee","year":"2023","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0460","doi-asserted-by":"crossref","first-page":"788159","DOI":"10.3389\/fneur.2021.788159","article-title":"Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine","volume":"12","author":"Mechtler","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","article-title":"The sense of stopping migraine prophylaxis","volume":"24","author":"Al-Hassany","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0470","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0475","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","article-title":"Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study","volume":"22","author":"Vernieri","year":"2021","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0480","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-023-11872-2","article-title":"Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study","author":"Vernieri","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0485","doi-asserted-by":"crossref","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","article-title":"Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study","volume":"99","author":"de Vries Lentsch","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.008_bib0490","doi-asserted-by":"crossref","first-page":"e209349","DOI":"10.1212\/WNL.0000000000209349","article-title":"Efficacy and safety of erenumab in participants with episodic migraine in whom 2-4 prior preventive treatments had failed: LIBERTY 3-Year Study","volume":"102","author":"Reuter","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.008_bib0495","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0500","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0505","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/03331024211037304","article-title":"Could erectile dysfunction be a side effect of CGRP inhibition? A case report","volume":"42","author":"Al-Hassany","year":"2022","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0510","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241248837","article-title":"Case reports: could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?","volume":"44","author":"Al-Hassany","year":"2024","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0515","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/0333102420933571","article-title":"Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: a case report","volume":"40","author":"Wurthmann","year":"2020","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0520","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231158083","article-title":"Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase\u00ae","volume":"43","author":"Noseda","year":"2023","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0525","doi-asserted-by":"crossref","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","article-title":"Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system","volume":"14","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0530","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2024.09.008_bib0535","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2024.09.008_bib0540","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0545","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0550","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.008_bib0555","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2024.09.008_bib0560","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.008_bib0565","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2024.09.008_bib0570","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0575","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10\u00a0mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0580","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.008_bib0585","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","article-title":"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA","volume":"402","author":"Dodick","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2024.09.008_bib0590","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/brain\/awaa211","article-title":"Differential medication overuse risk of novel anti-migraine therapeutics","volume":"143","author":"Saengjaroentham","year":"2020","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0595","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0333102420938652","article-title":"Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache","volume":"40","author":"Navratilova","year":"2020","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0600","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","article-title":"European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0605","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s10194-023-01676-0","article-title":"Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry","volume":"24","author":"Ruscheweyh","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0610","first-page":"CD008541","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"Law","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2024.09.008_bib0615","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221141686","article-title":"Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials","volume":"43","author":"Lipton","year":"2023","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0620","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s10194-023-01696-w","article-title":"Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis","volume":"24","author":"Naghdi","year":"2023","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2024.09.008_bib0625","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data","volume":"42","author":"Lanteri-Minet","year":"2022","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0630","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000207375","article-title":"Pregnancy outcomes in patients exposed to onabotulinumtoxina treatment: a cumulative 29-year safety update","volume":"101","author":"Brin","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.008_bib0635","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0640","unstructured":"Actualit\u00e9\u00a0\u2013\u00a0Topiramate et risques chez les enfants expos\u00e9s pendant la grossesse\u00a0: modification des conditions de prescription et de d\u00e9livrance aux femmes concern\u00e9es. ANSM n.d. https:\/\/ansm.sante.fr\/actualites\/topiramate-et-risques-chez-les-enfants-exposes-pendant-la-grossesse-modification-des-conditions-de-prescription-et-de-delivrance-aux-femmes-concernees-5 [accessed February 15, 2024]."},{"key":"10.1016\/j.neurol.2024.09.008_bib0645","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.008_bib0650","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.008_bib0655","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/03331024211047454","article-title":"TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine","volume":"42","author":"Chowdhury","year":"2022","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2024.09.008_bib0660","unstructured":"Information de s\u00e9curit\u00e9\u00a0\u2013\u00a0Valproate et d\u00e9riv\u00e9s: risque potenti. ANSM n.d. https:\/\/ansm.sante.fr\/informations-de-securite\/valproate-et-derives-risque-potentiel-de-troubles-neurodeveloppementaux-chez-les-enfants-dont-le-pere-a-ete-traite-dans-les-3-mois-qui-precedent-la-conception [accessed October 16, 2023]."},{"key":"10.1016\/j.neurol.2024.09.008_bib0665","doi-asserted-by":"crossref","first-page":"e2414709","DOI":"10.1001\/jamanetworkopen.2024.14709","article-title":"Valproate use during spermatogenesis and risk to offspring","volume":"7","author":"Christensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2024.09.008_bib0670","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","article-title":"European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine","volume":"24","author":"Deligianni","year":"2023","journal-title":"J Headache Pain"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724006003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724006003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:18:15Z","timestamp":1732742295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724006003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0035378724006003"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.09.008","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Migraine treatment: Position paper of the French Headache Society","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}